Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

	e of entity		ABN/ARSN
Sig	ma Pharmaceuticals Limited		15 088 417 403
We	(the entity) give ASX the following	information.	
Inf	formation about buy-back		
1	Type of buy-back	On-market buy-back	
2	Date Appendix 3C was given to ASX	(Associated Appendix	3D dated 2 October
		2014)	
	tal of all shares/units bought ve been received, before, and	back, or in relation to	which acceptances Previous day
	9	back, or in relation to on, previous day	-
	9	back, or in relation to on, previous day	-

5

	Before previous day			Previous day		
If buy-back is an on-market buy-back	Highest \$0.8525	price	paid:	Highest \$0.7550	price	paid:
	Lowest	prioc	paid:	Lowest \$0.7500	price	paid:
	\$0.5600	price	paiu.	Highest under \$0.7896	price a rule	llowed 7.33:

How many shares/units may still be bought back?

6	If the company/trust has disclosed						
	an intention to buy back	8					
	maximum number of shares/uni	ts					
	 the remaining number 	of					
	shares/units to be bought back						

21,229,223			

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:

Date: 28 November 2014

(Director/Company secretary)

Print name: SUE MORGAN

== == == ==